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The use of Mueller-Hinton agar supplemented with citrated human or citrated sheep blood was compared
with the use of routinely used Mueller-Hinton agar supplemented with defibrinated sheep blood for antimi-
crobial susceptibility testing of Streptococcus pneumoniae. The alternate supplements were found to be unsat-
isfactory, particularly for testing resistant isolates, and therefore are not recommended.
Streptococcus pneumoniae is a major cause of morbidity and
mortality in children worldwide (11, 15, 18). It is a fastidious
organism that requires a blood source for proper growth in
vitro and antimicrobial susceptibility testing (AST). Defi-
brinated sheep or horse blood is a common supplement for
blood agars, but pig or goat blood may also be used (2, 6, 14).
Defibrinated sheep blood Mueller-Hinton agar (DSBMHA) is
a standard medium used for AST of S. pneumoniae (1, 5).
Many resource-poor countries lack a regular supply of defi-
brinated animal blood and often use expired human blood
samples obtained from blood donors for medium preparation
(16; K. Edmond, personal communication) or blood samples
obtained from volunteers, such as laboratory members (19).
We previously reported that agar supplemented with citrated
sheep blood (easily collected in citrated human blood donor
packs) was suitable for the growth of S. pneumoniae but that
agar supplemented with citrated human blood was not (16).
We postulated that citrated sheep blood may be a suitable
supplement for AST of S. pneumoniae (16), and a similar
suggestion was also recently made by Yeh et al. (19). However,
when these studies are combined, only four different strains,
two of which being reference strains, were tested. Therefore,
the use of citrated human or citrated sheep blood for AST of
S. pneumoniae clinical isolates has not been appropriately val-
idated.
The aim of this study was to determine if Mueller-Hinton
agar containing citrated human or citrated sheep blood is a
suitable medium for AST of S. pneumoniae. We compared the
AST results obtained using the standardized disk diffusion and
Etest methods on citrated sheep blood Mueller-Hinton agar
(CSBMHA) and citrated human blood Mueller-Hinton agar
(CHuBMHA) to those obtained with the recommended me-
dium, DSBMHA. This study was approved by the Fiji National
Research Ethics Review Committee and the University of Mel-
bourne Human Research Ethics Committee.
Invasive S. pneumoniae isolates (in blood [n  59], cerebro-
spinal fluid [CSF] [n  7], pleural fluid [n  1], and joint
aspirate [n  1]) collected from the Colonial War Memorial
Hospital laboratory in Suva, Fiji, from July 2004 to October
2007 were tested for their susceptibility to antimicrobials using
disk diffusion. In order to include a substantial number of
nonsusceptible isolates, we also included 20 nasopharyngeal
carriage isolates (obtained from 17 infants participating in a
vaccine trial [17]) that were nonsusceptible (nonsusceptible
[NS], intermediate [I], or resistant [R]), or borderline non-
susceptible, to oxacillin, erythromycin, or co-trimoxazole by
disk diffusion on DSBMHA. These isolates were tested on
the other agars as described below.
DSBMHA, CSBMHA, and CHuBMHA plates were pre-
pared according to standard methods as previously described
(16). Blood was obtained from sheep of the breed Fiji Fantas-
tic, a hair sheep adapted for tropical conditions (3, 10), housed
at the Koronivia Research Station. To conduct disk diffusion
testing, isolates were made up to a 0.5 McFarland standard (up
to 1.0 if mucoid for repeat testing) in brain heart infusion broth
(Oxoid Ltd., Basingstoke, Hampshire, United Kingdom).
Lawn cultures were created, and disks (BD Difco, Franklin
Lakes, NJ) containing 1 g oxacillin, 15 g erythromycin, 1.25
g trimethoprim-23.75 g sulfamethoxazole (co-trimoxazole),
or 30 g chloramphenicol were added onto the 3 different agar
plates according to the Kirby-Bauer disk diffusion method (4),
as per the CLSI guidelines (5). This included weekly testing of
appropriate control strains (5). Plates were incubated in 5%
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CO2 at 35°C for 20 to 24 h. Isolates were categorized as sen-
sitive (S), intermediate (I), or resistant (R) for erythromycin
and co-trimoxazole and susceptible or nonsusceptible (NS) for
oxacillin and chloramphenicol, according to standard guide-
lines (13). Of the 68 invasive isolates tested, 13%, 4%, 25%,
and 0% were nonsusceptible (NS, I, or R) to oxacillin, eryth-
romycin, co-trimoxazole, and chloramphenicol, respectively, by
disk diffusion testing on DSBMHA. All included isolates were
sensitive to chloramphenicol, so this antibiotic was not exam-
ined further.
For the Etest method, a subset of isolates was examined (32
invasive and 20 carriage isolates). The 15, 9, and 21 isolates
that were nonsusceptible (that is, NS, I, or R) to oxacillin,
erythromycin, and co-trimoxazole, respectively, by disk diffu-
sion on DSBMHA had MICs determined for the correspond-
ing antibiotics on all three agars by the Etest method. Etest
strips (AB Biodisk, Solna, Sweden) containing benzylpenicillin,
erythromycin, or co-trimoxazole were added to lawn culture
agar plates, incubated under the same conditions as the disk
diffusion plates, and interpreted using the manufacturer’s in-
structions (1). MIC results were generally consistent with disk
diffusion testing. When tested on DSBMHA, 12/15 (80%), 9/9
(100%), and 15/21 (71%) isolates that were nonsusceptible
(NS, I, or R) by disk diffusion were also nonsusceptible (NS, I,
or R) by the Etest method for oxacillin-benzylpenicillin, eryth-
romycin, and co-trimoxazole, respectively.
The results from the use of disk diffusion and Etest methods
on CSBMHA and CHuBMHA were compared with the results
from the use of these methods on the gold-standard DSBMHA
for all isolates. Category agreement (disk diffusion), essential
agreement (Etest method), and the number of interpretative
category errors for each medium were determined for each
antibiotic (7). Category agreement documents the proportion
of isolates having the same category result (e.g., S/I/R) when
tested on DSBMHA. Essential agreement documents results
within one doubling dilution of the MIC obtained on DSBMHA. A
category or essential agreement of 90% was used to ini-
tially assess for acceptability as a medium for AST. Inter-
pretative category errors were defined as very major (classed
as S when I, R, or NS on DSBMHA), major (classed as I, R,
or NS when S on DSBMHA), or minor (all other errors).
The percentages of very major, major, and total errors were
determined by dividing by the number of R, S, and total
isolates tested, respectively (7). A very major and major
discrepancy rate of 3% each was also used as an accept-
ability criterion (7).
For disk diffusion testing (Table 1), the use of CHuBMHA and
CSBMHA resulted in unacceptable (co-trimoxazole [59% and
68%, respectively]) and acceptable (oxacillin [both 93%] and
erythromycin [92% and 90%, respectively]) category agree-
ment in comparison with DSBMHA. There were also a large
number of interpretative category errors, particularly for co-
trimoxazole (Table 1).
For the Etest method (Table 2), the use of CHuBMHA and
CSBMHA resulted in unacceptable essential agreement in
comparison with DSBMHA for penicillin (67% and 60%),
erythromycin (56% and 33%), and co-trimoxazole (52% and
57%), respectively. There were also a large number of inter-
pretative category errors for all antibiotics (Table 2).
To our knowledge, this is the first examination of the
validity of CHuBMHA for AST despite its common usage in
resource-poor settings. Overall, the results for CHuBMHA
and CSBMHA were too poor to recommend their use for
AST, despite CSBMHA being a suitable medium for culture
and identification of S. pneumoniae (16).
In terms of disk diffusion testing, CHuBMHA and CSBMHA
were suitable for oxacillin and erythromycin, while both media
were unsuitable for the testing of co-trimoxazole sensitivity
when the category agreement alone was used as a measure.
However, the characteristics of the isolates tested impacts on
the calculation and assessment of errors. For example, very
major errors will not be detected if the isolates are uniformly
sensitive (8, 12). When we analyzed the resistant isolates sep-
arately by determining the percentage of very major discrep-
ancies (7), we found that both media resulted in 3% very
major discrepancies for all three antibiotics (Table 1), although
for erythromycin, it must be noted that this was determined
using only seven isolates. Overall, neither CHuBMHA nor
CSBMHA were suitable for disk diffusion testing of oxacillin,
erythromycin, or co-trimoxazole.
For the Etest method, both CHuBMHA and CSBMHA
were unsatisfactory for all three antibiotics tested. This was
also the case when the carriage isolates were analyzed sepa-
rately (8), with all antibiotics on both media having an essential
agreement of 73% (data not shown).
Although the blood agars were tested with only four antibi-
TABLE 1. Comparison of disk diffusion testing of S. pneumoniae using CHuBMHA or CSBMHA with that using DSBMHA
Medium Antibiotic nc % CAb
No. of interpretative errors (%)a
Very major Major Minor Total
CHuBMHA Oxacillin 82 93 1 (5) 2 (3) 0 (0) 3
Erythromycin 77 92 2 (29) 0 (0) 1 (1) 3
Co-trimoxazole 82 59 11 (50) 4 (8) 2 (2) 17
CSBMHA Oxacillin 82 93 2 (10) 1 (2) 0 (0) 3
Erythromycin 77 90 1 (14) 1 (2) 2 (3) 4
Co-trimoxazole 82 68 3 (14) 3 (6) 7 (9) 13
a Interpretative errors are defined as very major (classed as S when I, R, or NS on DSBMHA), major (classed as I, R, or NS when S on DSBMHA), or minor (all
other) errors. The percentages of very major, major, and minor errors are calculated according to ISO 20776-2:2007(E), where the number of these errors are divided
by the number of resistant, sensitive, and total isolates, respectively, and expressed as percentages (7).
b Category agreement (CA) is the agreement of sensitive, intermediate, or resistant (or susceptible or nonsusceptible) isolates on test medium with those on reference
medium DSBMHA (7).
c n, number of isolates tested with the corresponding medium and antibiotic.
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otics, three of these constitute the “group A” set of antimicro-
bials recommended for primary testing and routine reporting
by CLSI (13). We note that chloramphenicol, an antibiotic
often used for treatment of invasive pneumococcal disease in
resource-poor settings, was not adequately assessed in this
study because only susceptible isolates were tested.
We did not elucidate the mechanisms for the interference of
citrated human and sheep blood on AST, but it may relate to
the presence of citrate, pH, reduced buffering capacity, con-
centrations of cations, changes due to the storage of human
blood, or other unidentified factor(s) (9, 13, 19). Only one
brand of Mueller-Hinton base agar was used, so further testing
would be required to determine whether these findings apply
to other brands. In addition, it would be important to deter-
mine if these results apply to other bacterial species.
These results have significant implications for settings where
defibrinated sheep blood is not readily available and alterna-
tives, such as imported blood or premade agar plates, are
prohibitively expensive. The development of suitable, practical
alternative agars and supplements should therefore be a pri-
ority. Others have suggested that citrated hair sheep blood is
an appropriate alternative medium supplement for AST (19).
However, the findings from this study suggest otherwise. We
therefore urge caution in interpreting S. pneumoniae AST
from laboratories unless it is clear that citrated human or
citrated sheep blood agar has not been used.
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Medium Antibiotic nc
No. of isolates with log2 ratios to reference
DSBMHA MIC
% EAb
No. of interpretative errorsa
3 2 1 0 1 2 3 Verymajor Major Minor Total
CHuBMHA Penicillin 15 0 2 2 9 1 0 1 67 2 1 0 3
Erythromycin 9 0 0 0 5 0 1 3 56 1 0 0 1
Co-trimoxazole 21 4 2 4 7 1 2 1 52 4 1 3 8
CSBMHA Penicillin 15 1 1 4 9 0 0 0 60 4 0 0 4
Erythromycin 9 1 0 1 2 0 2 3 33 1 0 1 2
Co-trimoxazole 21 0 1 2 6 9 2 1 57 0 4 6 10
a Interpretative errors are defined as very major (classed as S when I, R, or NS on DSBMHA), major (classed as I, R, or NS when S on DSBMHA), or minor (all
other) errors (7).
b Essential agreement occurs when the test MIC result is within a 1 doubling dilution of the MIC obtained on reference medium DSBMHA (7).
c n, number of isolates tested with the corresponding medium and antibiotic.
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